Roivant Sciences is trading at $35.05, up +4.53%, as biotech-sector momentum may be helping; no company-specific catalyst was identified. - No Roivant-specific announcement dated October 19 was identified; its listed latest press release is September 23. - Germany’s Merck agreed to acquire Silence Therapeutics for $1.3 billion, a notable biotech M&A development. - The deal is not specific to Roivant Sciences, pointing to a sector-wide rather than company-specific tailwind.